Brown & Brown (BRO) Q2 2026 Earnings Preview After a -35% Stock Slide
Key Takeaways
- Brown & Brown (BRO) is scheduled to release its second-quarter 2026 earnings on Monday, July 27, after the market closes, with a conference call set for Tuesday, July 28, at 8:00 a.m. EDT.
- Wall Street consensus estimates point to earnings of approximately $1.08 per share on revenue of roughly $1.72 billion, reflecting year-over-year growth of about 4.9% and 34%, respectively.
- The company has beaten earnings per share (EPS) estimates in four consecutive quarters, most recently posting $1.39 against a $1.36 consensus in Q1 2026.
- Organic growth trends, contingent commission performance, and progress on the Accession acquisition integration are expected to be the most closely watched metrics by investors.
- Analyst sentiment remains cautious but constructive, with a consensus Hold rating and an average 12-month price target near $74–$78, implying modest upside from recent trading levels.
- The stock has underperformed the broader market over the past year, declining approximately 35–37%, adding pressure on this quarter's results to restore confidence.
Why This Earnings Report Matters
Brown & Brown’s (BRO) Q2 2026 report lands at a pivotal moment for the insurance brokerage sector. After years of benefiting from hard market pricing in property and casualty (P&C) insurance, the industry now faces a softening rate environment that threatens to compress commission growth. BRO’s recent performance has been heavily influenced by its blockbuster Accession acquisition, which closed in late 2025 and drove 35.4% year-over-year revenue growth in Q1 2026. Investors are eager to see whether the company can sustain earnings momentum organically while integrating Accession, managing litigation-related client attrition, and navigating CAT (catastrophe) property rate declines. This report will serve as a critical temperature check on the broader insurance distribution landscape. I’m watching this closely because the results could signal how the rest of the sector is faring.
Earnings Expectations
The Zacks Consensus Estimate for BRO’s second-quarter 2026 earnings stands at $1.08 per share, representing a 4.9% increase from the $1.03 reported in Q2 2025. Revenue is expected to reach approximately $1.72 billion, a 34% jump year-over-year, largely attributable to the Accession acquisition. Some consensus trackers peg the EPS estimate slightly higher at $1.09. Notably, the EPS estimate has drifted modestly lower — down about 0.2% to 0.9% over the past 30 days — suggesting some analysts have trimmed expectations heading into the release.
On a segment level, analysts project Retail segment revenues of roughly $984.7 million (up 41.3% year-over-year), while commissions and fees are forecast at $1.70 billion. Investment income is expected to come in around $24.7 million, down approximately 29.4% from the prior-year period largely due to deployment of proceeds from BRO’s follow-on stock offering. Organic growth, a metric closely tracked by investors, is projected at approximately 0.9%, reflecting headwinds from CAT property rate softening and a pharmacy revenue-model transition within the Retail segment.
Brown & Brown carries a Zacks Rank #3 (Hold) and a positive Earnings ESP (Expected Surprise Prediction) of +0.31%, a combination that historically points to a roughly 70% probability of an earnings beat. The company’s four-quarter beat streak bolsters this outlook, though investors should note that even a modest beat may not guarantee a positive stock reaction — BRO shares fell approximately 4.2% after its Q1 2026 beat in April. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Market sentiment heading into BRO’s Q2 2026 report is notably cautious. The stock has shed roughly 35–37% of its value over the past 12 months, underperforming both the S&P 500 and the financial sector. Shares recently traded near $67–$69, hovering well above the 52-week low of $53.81 but far below the 52-week high of $104.97. Over the past month, however, the stock has staged a modest recovery, gaining approximately 10%, suggesting some investors are positioning for a favorable outcome.
Analyst activity in recent weeks reflects divided opinion. Morgan Stanley downgraded BRO to Underweight (equivalent to Sell) in early July, cutting its price target to $55 and citing concerns over slowing organic growth and mid-market competition. Conversely, Mizuho raised its target to $81 with an Outperform rating, while Keefe, Bruyette & Woods lifted its target to $74. Goldman Sachs and Raymond James also nudged targets higher. Among 19 analysts, the consensus rating remains Hold. Key risk factors heading into the print include potential disappointment on organic growth, CAT-related claims exposure from Midwest severe convective storms, lingering litigation-driven client departures (estimated at roughly $31 million annualized), and broader pricing-cycle headwinds across P&C lines.
Forward Outlook and Key Factors to Monitor
Looking beyond the Q2 2026 headline numbers, several critical themes will shape Brown & Brown’s trajectory through the remainder of fiscal 2026 and into 2027.
Accession Integration and Synergies. The Accession acquisition remains the single largest swing factor for BRO’s near-term financial performance. In Q1 2026, Accession contributed approximately $445 million in recognized revenue but also created a roughly 200-basis-point drag on consolidated adjusted EBITDAC (earnings before interest, taxes, depreciation, amortization, and change in contingent consideration). Management has targeted $30 million to $40 million in EBITDA synergies for the current year, with a full-year Accession adjusted EBITDAC margin goal of approximately 35%. Investors should monitor commentary on synergy realization, integration costs, and whether the margin trajectory is improving.
Organic Growth and Pricing Dynamics. Organic growth — particularly stripping out the lumpy impact of contingent commissions — is under the microscope. Management indicated on the Q1 call that Q2 organic growth excluding contingents would likely be relatively flat, with gradual sequential improvement expected through the back half of the year. The softening P&C pricing cycle, especially in property lines, remains a headwind. Any upside surprise on organic growth would likely be received positively, while a miss could reinforce bearish narratives around market saturation and competitive pressures.
Contingent Commissions. Profit-sharing contingent commissions surged by approximately $54 million in Q1 2026, driven by favorable underwriting results and Accession contributions. Management signaled that contingents should be up for the full year. Given that 2025 total contingent commissions were roughly $255 million, any meaningful deviation from this trajectory could materially impact full-year earnings.
Capital Allocation and Shareholder Returns. BRO repurchased $350 million in shares during Q1, reducing its share count by approximately 5 million, and raised its quarterly dividend by 10%. Investors should watch for updated commentary on the pace of buybacks, leverage reduction, and M&A (mergers and acquisitions) appetite, particularly as the company balances capital deployment between deleveraging and growth investments.
Using Tickeron’s AI Tools in My Research
In my analysis process, I frequently rely on Tickeron’s AI Screener to quickly compare insurance brokerage names like BRO against peers on key metrics such as earnings surprises, organic growth trends, and technical patterns. The platform’s customizable filters help surface relevant ideas efficiently ahead of earnings season without replacing traditional fundamental work. It has become a useful addition to my regular workflow for staying organized during busy reporting periods.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for BRO shows an upward move is likely
BRO's Aroon Indicator triggered a bullish signal on August 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 296 similar instances where the Aroon Indicator showed a similar pattern. In of the 296 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BRO advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BRO moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where BRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BRO as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BRO turned negative on August 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BRO broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.904) is normal, around the industry mean (8.009). P/E Ratio (22.879) is within average values for comparable stocks, (36.010). BRO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.729). Dividend Yield (0.009) settles around the average of (0.014) among similar stocks. P/S Ratio (3.611) is also within normal values, averaging (3.220).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of insurance brokerage services and casualty insurance underwriting services
Industry InsuranceBrokersServices
Advertisement